Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by cardman503on Aug 21, 2012 1:20pm
276 Views
Post# 20242548

RE: RE: RE: RE: RE: NR

RE: RE: RE: RE: RE: NR

Here are the highlights of the original NR- I notice production is lower and watercut is higher now- but I am pleased that there is still life in this company and perhaps an opportunity to recoup some of the losses, with more good news and patience.

Best, cardman

Une Formation Test

On June 21, 2012, the Company announced a new oil discovery in the Une formation of the Flami-1 well. Testing operations commenced on June 13, 2012 with the Une formation being perforated at the 9,086-9,100 foot interval.

Phase 1 of the test involved producing out the drilling control fluids and cleaning the wellbore. Over a 60 hour period the well produced 1,514 BOPD of 15.5 degree API oil with an average watercut of 13%. Cumulative oil production over those 60 hours was 3,786 barrels of oil.

Following Phase 1 of the test the well was shut in to perform a 24 hour pressure build-up test. During this time, the formation pressure was measured at 3,850 psi.

Phase 2 of the test involved periodically stepping up the total fluid production rate to observe watercut and overall fluid production. Cumulative production over a 73 hour period was 5,496 barrels of oil and was produced in the following stages:

1.  Stage 1: Over an initial period of 29 hours the well produced 1,403 BOPD    (1,695 total over 29 hours) with an average watercut of 20%; 2.  Stage 2: The drawdown rate was increased and over a period of 20 hours    the well produced 1,832 BOPD (1,527 total over 20 hours) with a watercut    of 12%; 3.  Stage 3: The drawdown rate was increased and over a period of 15 hours    the well produced 2,160 BOPD (1,350 total over 15 hours) with a watercut    of 12%; 4.  Stage 4: The drawdown rate was increased and over a period of 9 hours    the well produced 2,464 BOPD (924 total over 9 hours) with a 12%    watercut. 

These test results are preliminary and are not necessarily an indication of the longer-term potential of the well. Additional tests will be performed once the well can be placed on an extended test.

Mirador Formation Test

Testing operations commenced on July 1, 2012 with the Mirador formation being perforated at the 8,364-8,372 foot interval. Over a 48 hour test, the Mirador formation produced a total of 510 barrels of oil, and 1,448 barrels of water. The calculated average daily rate over the two days was 299 BOPD, and 899 BWPD for a 75% watercut.

Given the lower productivity and higher watercut of the Mirador formation, it was decided to terminate testing of the Mirador formation and move towards an application to place the Une formation of the well on extended production test. The well will now be shut in while an application is made to the Ministry of Mines and Energy in Colombia to put the well on an extended test. This application approval is expected to take four to six weeks, at which time the well can be put back on production and oil from the extended test sold to market.

Santa Maria is paying 50% of the total cost of the well and will earn 45.275% of production before payout and 34.25% of production after payout under a private participating interest agreement.

Bullboard Posts